Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on July 6, 2021. The filing serves as a Regulation FD disclosure and reports on other events regarding the Company's lead drug candidate, AD04, which is being investigated for the treatment of Alcohol Use Disorder (AUD) in patients with specific serotonin-related genotypes.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial progress.
Material Changes and Clinical Trial Updates
The Company provided a significant update on its ONWARD pivotal Phase 3 clinical trial:
- Screening: 100% of anticipated subjects have been screened (1,254 subjects).
- Enrollment: 90% of projected enrollment has been achieved (261 of 290 subjects).
- Genotype Match: 33% of evaluated patients tested positive for the AD04-associated genotype.
- Safety Profile: AD04 appears well-tolerated; the vast majority of adverse events are mild, and no study drug-related serious adverse events have been observed to date.
- Retention: The study retention rate is 84%.
Guidance, Outlook, and Risks
Outlook: The Company projects that data from the ONWARD trial will be provided in the first quarter of 2022.
Risks and Contingencies: The trial remains blinded, meaning the specific efficacy results comparing AD04 to placebo are not yet known. The filing explicitly states that the information provided is not "filed" for purposes of Section 18 of the Securities Exchange Act and shall not be incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the final enrollment numbers and the total count of patients with the target genotype once the trial concludes.
- Monitor the release of unblinded efficacy data expected in Q1 2022.
- Confirm the safety profile remains consistent as the trial moves toward completion.
- Review the full text of the press release furnished as Exhibit 99.1 for additional details not summarized in the 8-K.